Hints and tips:
...There has been no major medical breakthrough since Eisai’s Aricept, the most widely prescribed treatment for Alzheimer’s disease, became available in the US in 1997....
...Eisai has been developing medicine to combat dementia since the early 1980s and is best known for Donepezil, the most widely prescribed treatment for Alzheimer’s disease, which was originally developed as Aricept...
...“I’ve been sceptical of the amyloid hypothesis for a long time, and in particular of approaches that use the immune system to deal with amyloid,” says Dr Lawrence Friedhoff, the scientist behind Aricept,...
...Yet it is not drugs that account for the lion’s share of the costs — one of the most popular treatments for mitigating the worst effects of Alzheimer’s, Donepezil, often sold under the brand name Aricept...
...clinical studies, but Axovant’s 32-year-old founder, Vivek Ramaswamy, believed he had spotted a glimmer of hope in one study that suggested the medicine might work when added to an existing therapy called Aricept...
...on Tuesday said researchers had begun a so-called Phase III trial of the drug, codenamed RVT-101, which will be tested on 1,150 patients with a mild to moderate form of the disease in combination with Aricept...
...Donepezil, developed originally as Aricept by Eisai of Japan, was the first in a class of Alzheimer’s treatments known as cholinesterase inhibitors....
...The development of RVT-101 is being led at Axovant by Larry Friedhoff, who previously developed Aricept, one of the best-selling Alzheimer’s medicines....
...The only treatments with any evidence behind them are for Alzheimer’s disease rather than vascular dementia: donepezil (Aricept), galantamine (Reminyl) and rivastigmine (Exelon)....
...The company chose to go it alone rather than to tie up with a local player to sell its Alzheimer drug Aricept and its acid reflux therapy AcipHex....
...Eisai’s best-selling drug Aricept, a medication for Alzheimer’s disease, is the only such drug approved in Japan....
...For Eisai, its Aricept patent – an Alzheimer’s drug – expires in 2010. The patent on Astellas’s transplant drug Prograf expired in the US a year ago and will do so in Europe next month....
...Nice, the National Institute of Health and Clinical Excellence, argued that the benefits of drugs, including Eisai’s Aricept, which costs the NHS £2.50 per patient per day, outweighed the costs only for...
...advised against NHS use of costly new drugs including GlaxoSmithKline’s antiviral flu drug Relenza, its first decision, to more recent rejections of Pfizer’s oral insulin Exubera for diabetics and Eisai’s Aricept...
...Eisai, which has signalled it intends to remain independent, has recently been expanding overseas and diversifying to counter its reliance on two drugs – Aricept for Alzheimers, whose patent expires in Japan...
...Eisai, which makes Aricept, is being joined in the judicial review challenge by Shire, which produces Reminyl, and the Alzheimer's Society, which represents about 630,000 sufferers....
...The case was bought by Eisai, a Japanese pharmaceutical company, which is the licensed holder of Aricept, one of the drugs Nice recommends for use by the National Health Service for Alzheimer’s....
...The legal challenge was launched last November by Eisai, which makes Aricept, one of the drugs at the centre of the case, and Pfizer, which distributes it in Britain....
International Edition